2019³â Á¦58Â÷ ´ëÇÑÇÙÀÇÇÐȸ Ãá°èÇмú´ëȸ : 2019-05-04±³À°ÀÏÀÚ : 2019-05-04
±³À°Àå¼Ò : ±×·£µåÇöóÀÚ Ã»ÁÖÈ£ÅÚ 3Ãþ ±×·£µåº¼·ë
±³À°ÁÖÁ¦ :
2019³â Á¦58Â÷ ´ëÇÑÇÙÀÇÇÐȸ Ãá°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇÑÇÙÀÇÇÐȸ
´ã´çÀÚ : ³²Àº°æ
¿¬¶ôó : 02-745-2040
À̸ÞÀÏ :
ksnm@ksnm.or.kr ±³À°Á¾·ù : ÇÙÀÇÇаú
Âü¼®¿¹»óÀοø : 350¸í
Èñ¸ÁÆòÁ¡ : 6Á¡ (ÀÏ¹Ý 5Á¡ / Çʼö 1Á¡)
Áö¿ª :
ÃæûºÏµµ±³À°½Ã°£ : 7 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í Á¤È¸¿ø 40,000Á¤È¸¿ø(±ºÀÇ°ü/°øÁߺ¸°ÇÀÇ) 25,000ÁØȸ¿ø 40,000¼ö·Ãȸ¿ø 25,000ºñȸ¿ø 80,000
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 08:40~09:00 Hyperthyroidism and its treatment ±èÀÎÁÖ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 09:00~09:20 Clinical guideline of RAI Tx in hyperthyroidism Á¤½Å¿µ(Ä¥°î°æºÏ´ëº´¿ø)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 09:20~09:40 Clinical experience in RAI Tx in hyperthyroidism ½ÅÁß¿ì(³ªºñ»ù¿¬ÇÕÀÇ¿ø)
ÈÞ½Ä 05-04 ±×·£µåº¼·ë 09:40~09:50 Coffee Break Coffee Break(Coffee Break)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 09:50~10:20 Current perspective of Zr-89 use À±Áرâ(¾ÆÁÖÀÇ´ë)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 10:20~10:35 Production and supply of Zr-89 in Korea ±èÁ¤¿µ(Çѱ¹¿øÀÚ·ÂÀÇÇпø)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 10:35~10:50 Labeling methods in Zr-89 use ÀÌÀ±»ó(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 10:50~11:05 Experience of Zr-89 use °¿øÁØ(¿¬¼¼ÀÇ´ë)
Åä·Ð 05-04 ±×·£µåº¼·ë 11:05~11:20 Discussion Discussion(Discussion)
ÈÞ½Ä 05-04 ±×·£µåº¼·ë 11:20~11:30 Coffee Break Coffee Break(Coffee Break)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 11:30~11:50 Experiences in multicenter clinical trials for imaging studies: cardiac CT ÃÖº´¿í(¿¬¼¼ÀÇ´ë)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 11:50~12:10 Experiences in multicenter clinical trials for invasive studies: FFR registry µµÁØÇü(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 12:10~12:30 Where are we headed? Perspectives for multicenter clinical trials in nuclear cardiology Á¶»ó°Ç(Àü³²ÀÇ´ë)
½Ä»ç 05-04 ±×·£µåº¼·ë 12:30~13:30 Á¡½É Á¡½É(Á¡½É)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 13:30~13:50 ÀÇ·á°¨¿°°ü¸®: Multidose vial »ç¿ëÀÇ ±¹³» ÇöȲ°ú ÁÖÀÇ »çÇ× ÀÌ»óÁÖ(¼¿ï¾Æ»êº´¿ø)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 13:50~14:10 ÀÇ·á°¨¿°°ü¸®: ÀÓ»ó°Ë»ç ¼öÇà¿¡ ´ëÇÑ °¨¿°°ü¸®ÀÇ ±¹Á¦ °¡À̵å¶óÀÎ ÀÌÈ£¿µ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 14:10~14:30 ÀÇ·á°¨¿°°ü¸®: ÀÓ»ó°Ë»ç ¼öÇàÀÇ °¨¿°°ü¸® ½Ç¹« ¹ÚÁ¤¹Ì(¼øõÇâÀÇ´ë)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 14:30~14:55 PRRT experience in Korea °°Ç¿í(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 14:55~15:20 Issues in use of radioactive drug in Korea ¿À½ÂÁØ(¿ï»êÀÇ´ë)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 15:20~15:45 In a view point of MFDS in use of radioactive drug À̳²Èñ(½ÄÇ°ÀǾàÇ°¾ÈÀüó)
Åä·Ð 05-04 ±×·£µåº¼·ë 15:45~16:00 Discussion Discussion(Discussion)
ÈÞ½Ä 05-04 ±×·£µåº¼·ë 16:00~16:10 Coffee Break Coffee Break(Coffee Break)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 16:10~16:30 Immuno-oncology the Basics ±èÀÎÈ£(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 16:30~16:50 Immuno-oncology and Imaging Biomarkers ÃÖÈ«À±(¼¿ïÀÇ´ë)
±³À°½Ã°£ 05-04 ±×·£µåº¼·ë 16:50~17:10 Immuno-oncology and Theranostics: Therapy º¯º´Çö(Çѱ¹¿øÀÚ·ÂÀÇÇпø)